Market Overview - The Hong Kong stock market opened slightly lower on December 31, with the Hang Seng Index down 0.21% at 25,801.49 points, the Hang Seng Tech Index down 0.22% at 5,566.24 points, and the National Enterprises Index down 0.23% at 8,970.49 points [1] - Major tech stocks mostly declined, with Alibaba down 0.55%, Tencent down 0.42%, and JD.com down 1.32%. Conversely, Xiaomi rose by 0.86% [1] Company News - Zijin Mining (02899.HK) expects to achieve a net profit of approximately RMB 51-52 billion for the fiscal year 2025, representing a year-on-year increase of about 59%-62% due to increased production and sales prices [2] - Starry Development (00640.HK) reported revenue of approximately HKD 835 million for the fiscal year ending September 30, 2025, a year-on-year increase of 13.4%, and a net profit of approximately HKD 122 million, up 21.7% [2] - Shanghai Electric (02727.HK) plans to sell a 47.4% stake in Electric Guoxuan and waive its preemptive rights to an additional 3.6% stake [3] - CNOOC Services (02883.HK) has recently purchased bank wealth management products totaling HKD 3 billion [4] Clinical Trials and Drug Approvals - Fosun Pharma (02196.HK) has initiated clinical trials for its integrated diagnosis and treatment nuclear medicine project SRT-007 within China [5] - Hutchison China MediTech (00013.HK) announced that its new drug application for Savolitinib, intended for treating gastric cancer patients with MET amplification, has been accepted and prioritized for review [5] Strategic Partnerships - Linkong Biotechnology Group (00690.HK) has established a strategic partnership with Wenzhou Medical University National Engineering Research Center and the Ouhai District People's Government [6] Financing Activities - Youlian International Education Leasing (01563.HK) has entered into a financing lease agreement for energy-saving equipment [7] Stock Buybacks - Tencent Holdings (00700.HK) repurchased 1.062 million shares for HKD 636 million at prices ranging from HKD 594.5 to HKD 600.5 [8] - COSCO Shipping Holdings (01919.HK) repurchased 4.3715 million shares for HKD 61.05 million at prices between HKD 13.86 and HKD 14.06 [9] - China Feihe (06186.HK) repurchased 8.837 million shares for HKD 36.34 million at prices between HKD 4.07 and HKD 4.12 [10] - Kuaishou-W (01024.HK) repurchased approximately 464,000 shares for HKD 29.88 million at prices between HKD 63.75 and HKD 64.75 [10] - Giant Bio (02367.HK) repurchased 400,000 shares for HKD 13.44 million at prices between HKD 33.48 and HKD 33.76 [11] Institutional Insights - Everbright Securities notes that the overall profitability of Hong Kong stocks remains strong, with relatively scarce assets in internet, new consumption, and innovative pharmaceuticals. Despite recent gains, valuations are still considered low, suggesting long-term investment potential [12] - Founder Securities highlights positive signals from government policies aimed at optimizing the "two new" policies, which may enhance the competitive environment in the automotive industry [12] - CITIC Securities anticipates a 7.9% increase in Hong Kong private residential transaction volumes in 2026, driven by a favorable interest rate environment and increased asset allocation demand [12]

Major Events - Cloudtop New Horizon (01952) has its original product, Nanfukang®, protected by patent ZL200980127272.5 in China, which is currently valid [1] - Linkang Biotechnology Group (00690) has reached a strategic cooperation with Wenzhou Medical University National Engineering Research Center and the People's Government of Ouhai District, Wenzhou [1] - Auhua Pharmaceutical (00013) announced that the new drug application for Savolitinib for treating gastric cancer patients with MET amplification has been accepted and included in priority review in China [1] - Fosun Pharma (02196) has initiated Phase I clinical trials for its integrated diagnosis and treatment nuclear medicine project SRT-007 within China [1] - Postal Savings Bank of China (01658) has received approval from the National Financial Supervision Administration for the absorption and merger with Postal Huai Wanjia Bank [1] - MicroPort Cardiac Devices-B (02160) has officially published the one-year follow-up results of the early feasibility study for AltaValveTM [1] Operating Performance - New Fire Technology Holdings (01611) reported an annual loss attributable to shareholders of HKD 9.212 million, a shift from profit to loss year-on-year [1] - Xingqian Development (00640) reported an annual net profit of approximately HKD 122 million, an increase of 21.7% year-on-year [1] - Zijin Mining Group (02899) expects a net profit attributable to shareholders of approximately RMB 51-52 billion for the fiscal year 2025, representing a year-on-year increase of about 59%-62% [1] - Zijin Gold International (02259) issued a profit warning, expecting a net profit attributable to shareholders of approximately USD 1.5-1.6 billion for 2025, a year-on-year increase of about 212%-233% [1]

Core Viewpoint - The company reported a revenue of approximately HKD 835 million for the fiscal year ending September 30, 2025, reflecting a year-on-year growth of 13.4% and a net profit of approximately HKD 122 million, which is a 21.7% increase compared to the previous year [1] Group 1: Financial Performance - Revenue increased primarily due to sustained growth in footwear consumption in the Asia-Pacific region, contributing to revenue growth across all geographic areas [1] - Basic earnings per share were reported at HKD 0.4338, with a proposed final dividend of HKD 0.103 per ordinary share [1]

公告称，收益增加主要是由于在亚太区域鞋履消费开支持续增加的支持下，期内所有地理区域的收益贡 献增加所致。 智通财经APP讯，星谦发展(00640)公布截至2025年9月30日止年度业绩，收益约8.35亿港元，同比增长 13.4%;净利约1.22亿港元，同比增长21.7%;基本每股盈利43.38港仙，拟派末期股息每股普通股10.3港 仙。 ...

香港交易及結算所有限公司、香港聯合交易所有限公司及新加坡證券交易所有限 公司對本公告之內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確 表示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致之任何 損失承擔任何責任。 INFINITY DEVELOPMENT HOLDINGS COMPANY LIMITED 星 謙 發 展 控 股 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （香港股份代號：640） （ 公司註冊編號：234794 ） （新加坡股份代號：ZBA） 截至二零二五年九月三十日止年度之年度業績公告 星謙發展控股有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此公佈本公司 及其附屬公司（統稱「本集團」）截至二零二五年九月三十日止年度之經審核綜合 年度業績，連同截至二零二四年九月三十日止年度之比較數字。本公司審核委員 會（「審核委員會」）已審閱本集團截至二零二五年九月三十日止年度之年度業績。 綜合損益及其他全面收益表 截至二零二五年九月三十日止年度 | | | | | 增加╱ | | --- | --- | --- | --- | --- | ...

热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 公告称，收益增加主要是由于在亚太区域鞋履消费开支持续增加的支持下，截至2025年9月30日止年度 所有地理区域的收益贡献增加所致。 责任编辑：卢昱君 星谦发展（00640）发布截至2025年9月30日止年度业绩，该集团取得收益8.35亿港元，同比增加 13.4%；公司拥有人应占年内溢利1.22亿港元，同比增加21.7%；每股基本（经重列）盈利43.38港仙， 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 星谦发展（00640）发布截至2025年9月30日止年度业绩，该集团取得收益8.35亿港元，同比增加 13.4%；公司拥有人应占年内溢利1.22亿港元，同比增加21.7%；每股基本（经重列）盈利43.38港仙， 拟派发末期股息每股10.3港仙。 拟派发末期股息每股10.3港仙。 公告称，收益增加主要是由于在亚太区域鞋履消费开支持续增加的支持下，截至2025年9月30日止年度 所有地理区域的收益贡献增加所致。 责任编辑：卢昱君 ...

智通财经APP讯，星谦发展(00640)发布公告，将于2026年2月23日派发截至2025年9月30日止年度的末期 股息每股0.103港元。 ...

Core Viewpoint - The company reported a revenue of HKD 835 million for the fiscal year ending September 30, 2025, reflecting a year-on-year increase of 13.4% [1] - The profit attributable to shareholders reached HKD 122 million, marking a year-on-year growth of 21.7% [1] - The basic earnings per share (after restatement) were HKD 0.4338, with a proposed final dividend of HKD 0.103 per share [1] Revenue Growth - The increase in revenue is primarily attributed to the continued growth in footwear consumption in the Asia-Pacific region [1] - All geographical regions contributed to the revenue growth for the fiscal year ending September 30, 2025 [1]

公告称，收益增加主要是由于在亚太区域鞋履消费开支持续增加的支持下，截至2025年9月30日止年度 所有地理区域的收益贡献增加所致。 星谦发展(00640)发布截至2025年9月30日止年度业绩，该集团取得收益8.35亿港元，同比增加13.4%;公 司拥有人应占年内溢利1.22亿港元，同比增加21.7%;每股基本(经重列)盈利43.38港仙，拟派发末期股息 每股10.3港仙。 ...

星谦发展(00640)发布公告，将于2026年2月23日派发截至2025年9月30日止年度的末期股息每股0.103港 元。 ...